Ilan Kirsch

1.5k total citations
11 papers, 257 citations indexed

About

Ilan Kirsch is a scholar working on Cancer Research, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ilan Kirsch has authored 11 papers receiving a total of 257 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Cancer Research, 5 papers in Oncology and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ilan Kirsch's work include Cancer Genomics and Diagnostics (6 papers), Acute Lymphoblastic Leukemia research (5 papers) and CAR-T cell therapy research (4 papers). Ilan Kirsch is often cited by papers focused on Cancer Genomics and Diagnostics (6 papers), Acute Lymphoblastic Leukemia research (5 papers) and CAR-T cell therapy research (4 papers). Ilan Kirsch collaborates with scholars based in United States and Italy. Ilan Kirsch's co-authors include Naomi Winick, Yunfeng Dai, David Williamson, Elizabeth A. Raetz, Meenakshi Devidas, Harlan Robins, Eric Larsen, Charles Gawad, William L. Carroll and Mignon L. Loh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Transplantation and Cellular Therapy.

In The Last Decade

Ilan Kirsch

9 papers receiving 256 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ilan Kirsch United States 5 133 111 100 90 59 11 257
Lüder Hinrich Meyer Germany 10 116 0.9× 170 1.5× 144 1.4× 36 0.4× 44 0.7× 24 381
Sitaram Ghogale India 12 95 0.7× 197 1.8× 174 1.7× 71 0.8× 16 0.3× 29 320
Sarah Inglott United Kingdom 9 99 0.7× 74 0.7× 100 1.0× 14 0.2× 25 0.4× 15 237
Lars Fransecky Germany 8 104 0.8× 60 0.5× 99 1.0× 21 0.2× 34 0.6× 14 267
Federica Lovisa Italy 11 60 0.5× 83 0.7× 63 0.6× 92 1.0× 86 1.5× 23 271
Yongsheng Ruan China 9 73 0.5× 70 0.6× 116 1.2× 16 0.2× 27 0.5× 32 239
Lucia Anna De Novi Italy 8 91 0.7× 134 1.2× 145 1.4× 113 1.3× 60 1.0× 14 295
Maria Laura Milani Italy 6 176 1.3× 118 1.1× 118 1.2× 90 1.0× 5 0.1× 11 326
Jolien De Bie Belgium 6 52 0.4× 92 0.8× 111 1.1× 26 0.3× 47 0.8× 12 273
Marcela Braga Mansur Brazil 12 66 0.5× 219 2.0× 175 1.8× 26 0.3× 36 0.6× 28 341

Countries citing papers authored by Ilan Kirsch

Since Specialization
Citations

This map shows the geographic impact of Ilan Kirsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilan Kirsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilan Kirsch more than expected).

Fields of papers citing papers by Ilan Kirsch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilan Kirsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilan Kirsch. The network helps show where Ilan Kirsch may publish in the future.

Co-authorship network of co-authors of Ilan Kirsch

This figure shows the co-authorship network connecting the top 25 collaborators of Ilan Kirsch. A scholar is included among the top collaborators of Ilan Kirsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilan Kirsch. Ilan Kirsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Zhang, Amy, Kara L. Davis, Sneha Ramakrishna, et al.. (2025). Establishing Concordance of Next Generation Sequencing and Flow Cytometry Measures of B-Cell Recovery Post-CAR T Cell Therapy in B-ALL. Transplantation and Cellular Therapy. 31(2). S205–S206.
2.
3.
Frank, Matthew J., Nasheed Hossain, Ali Bukhari, et al.. (2021). Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. Journal of Clinical Oncology. 39(27). 3034–3043. 87 indexed citations
4.
Oliva, Stefania, Elisa Genuardi, Angelo Belotti, et al.. (2020). Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM).. Journal of Clinical Oncology. 38(15_suppl). 8533–8533. 14 indexed citations
5.
Frank, Matthew J., Nasheed Hossain, Ali Bukhari, et al.. (2019). Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma. Blood. 134(Supplement_1). 884–884. 14 indexed citations
6.
Frank, Matthew J., Nasheed Hossain, Ali Bukhari, et al.. (2019). Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.. Journal of Clinical Oncology. 37(15_suppl). 7552–7552. 6 indexed citations
7.
Wood, Brent L., David Wu, Beryl Crossley, et al.. (2017). Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 131(12). 1350–1359. 130 indexed citations
8.
Zimmermann, Marita, Ilan Kirsch, & Josh J. Carlson. (2017). Measurable Residual Disease (MRD) Testing in Multiple Myeloma Using an Improved Testing Technology: Population Impact. Blood. 130. 4685–4685. 1 indexed citations
9.
10.
Sala‐Torra, Olga, Megan Othus, David Williamson, et al.. (2014). Minimal Residual Disease Detection By Next Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia (ALL) Patients Treated on SWOG Trial S0333. Blood. 124(21). 2399–2399. 2 indexed citations
11.
Wu, David, Ryan Emerson, Anna Sherwood, et al.. (2013). Robust Detection Of Minimal Residual Disease In Unselected Patients With B-Cell Precursor Acute Lymphoblastic Leukemia By High-Throughput Sequencing Of IGH. Blood. 122(21). 2550–2550. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lüder Hinrich Meyer Breakdown of academic impact, for papers by Sitaram Ghogale Breakdown of academic impact, for papers by Sarah Inglott Breakdown of academic impact, for papers by Lars Fransecky Breakdown of academic impact, for papers by Federica Lovisa Breakdown of academic impact, for papers by Yongsheng Ruan Breakdown of academic impact, for papers by Lucia Anna De Novi Breakdown of academic impact, for papers by Maria Laura Milani Breakdown of academic impact, for papers by Jolien De Bie Breakdown of academic impact, for papers by Marcela Braga Mansur
Rankless by CCL
2026